Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 72Cr 62Cr 58Cr 53Cr 99Cr 6.89TCr 101.19Cr 682.76Cr 266.15Cr 3.45TCr 270.51Cr 264.63Cr 11TCr P/E 2026 *
3.56x
P/E 2027 * 3.46x
Enterprise Value 72Cr 62Cr 58Cr 53Cr 99Cr 6.89TCr 101.19Cr 682.76Cr 266.15Cr 3.45TCr 270.51Cr 264.63Cr 11TCr EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.46x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-5.85%
1 week+1.35%
Current month-2.25%
1 month+7.40%
3 months+5.48%
6 months+4.42%
Current year+22.70%
1 week 3.96
Extreme 3.96
4.49
1 month 3.55
Extreme 3.55
4.59
Current year 2.95
Extreme 2.95
5.78
1 year 1.01
Extreme 1.01
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Free

Chief Technology Officer

1,37,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-1,27,890 0.0777%
23/02/26 Sell

Chief Executive Officer

1,98,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
-5.85%+1.35%+275.91%-57.46% 72Cr
-0.65%+11.91%+79.18%+38.36% 38TCr
-0.22%-1.04%+23.65%-12.60% 7.01TCr
-1.04%+5.91%+49.89%+150.16% 1.22TCr
+1.37%+1.27%-1.11%+2.28% 855.43Cr
+1.41%-1.93%-11.46%0.00% 480.48Cr
+4.77%+0.36%-26.71%+19.47% 427.06Cr
+8.85%-17.60%-20.67%+23.50% 319.81Cr
-2.33%+1.16%+11.75%+51.94% 282.15Cr
+1.95%-3.11%-7.80%-4.20% 212.85Cr
Average +0.77%+0.09%+37.26%+21.15% 4.84TCr
Weighted average by Cap. -0.55%+11.09%+66.01%+32.27%

Financials

2026 *2027 *
Net sales 47Cr 40Cr 38Cr 35Cr 65Cr 4.51TCr 66Cr 446.93Cr 174.22Cr 2.26TCr 177.08Cr 173.22Cr 7.49TCr 49Cr 42Cr 39Cr 36Cr 68Cr 4.73TCr 69Cr 468.04Cr 182.45Cr 2.37TCr 185.44Cr 181.41Cr 7.84TCr
Net income 20Cr 17Cr 16Cr 15Cr 28Cr 1.94TCr 29Cr 192.63Cr 75Cr 974.73Cr 76Cr 75Cr 3.23TCr 22Cr 19Cr 18Cr 16Cr 30Cr 2.1TCr 31Cr 208.37Cr 81Cr 1.05TCr 83Cr 81Cr 3.49TCr
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
20/26/20 $4.140 -5.05% 5,43,602
19/26/19 $4.360 +1.16% 14,78,134
18/26/18 $4.310 -1.15% 14,11,493
17/26/17 $4.360 +1.16% 13,77,034
14/26/14 $4.310 +5.64% 23,34,027
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.360USD
Average target price
6.100USD
Spread / Average Target
+39.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock